Elekta to buy Resonant Medical for nearly $30M

Justine Varieur Cadet | | Health Imaging | Oncology Imaging
Clarity image-guided radiation therapy for patient. Image source: Resonant Medical & Elekta
Elekta is seeking to acquire Resonant Medical for $28.5 million in cash for the outstanding shares of Resonant, in order to add image guidance technologies, as well as R&D resources in the field of oncology imaging and motion management to its portfolio.

Montreal-based Resonant develops systems for image-guided radiation therapy of soft tissues using 3D ultrasound technology, especially in the breast and pelvic area. According to Stockholm-based Elekta, Resonant’s current products will continue to operate with linear accelerators from other manufacturers.

Resonant was founded in 2000 based on research from McGill University in Montreal. The company’s CEO, Tony Falco, PhD, is one of the founders and has more than 15 years experience in imaging technology. The company has 35 employees, most of whom are based in Montreal.

While the acquisition is subject to customary closing conditions, Elekta expects to consolidate Resonant into its accounts today.

Justine Varieur Cadet

Related Content

MRI guidance significantly reduces radiotherapy side effects compared to CT
Interventional procedure often as effective as surgery for difficult-to-treat liver cancer
AI tumor volume estimations could improve prostate cancer treatment strategies
MRI could be 'powerful tool' for guiding surgery decisions in patients with rectal cancer
Breast cancer only visible via MRI is often less aggressive
Breast cancer rates are on the rise, new report reveals

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.